Author

Ahad Sabet

Institution: ICON PLC (Ireland)

Observed institutions: ICON PLC (Ireland), PRA Health Sciences

ORCID: 0009-0004-7266-3310

Observed ORCID: 0009-0004-7266-3310

OpenAlex ID: A5077049998

Safety and efficacy of pioglitazone for the delay of cognitive impairment in people at risk of Alzheimer's disease (TOMMORROW): a prognostic biomarker study and a phase 3, randomised, double-blind, placebo-controlled trial

2021 · Daniel K Burns, Robert C Alexander, et al. · The Lancet Neurology · 145

A large multicentre, randomized, double‐blind, cross‐over study in healthy volunteers to compare pharmacokinetics, pharmacodynamics and safety of a pegfilgrastim biosimilar with its US‐ and EU‐reference biologics

2020 · Anne Bellon, Jessie Wang, et al. · British Journal of Clinical Pharmacology · 12

A Randomised Controlled Trial Comparing the Pharmacokinetics and Tolerability of the Proposed Adalimumab Biosimilar MSB11022 Delivered via Autoinjector and Pre-filled Syringe in Healthy Subjects

2022 · Ahad Sabet, Daniel S. Dickerson, et al. · Rheumatology and Therapy · 8

Bioequivalence and the food effect of macitentan/tadalafil 10/20 fixed‐dose combination tablets versus the use of single‐component tablets in healthy subjects

2024 · Jennifer Lynn Ford, Ahad Sabet, et al. · Pharmacology Research & Perspectives · 3

A Phase 1 Single-dose Bioavailability Study of an Oral Cenobamate Suspension Formulation (P11-10.007)

2026 · Vijaykumar Vashi, Louis Ferrari, et al. · Neurology

Pharmacokinetic, Safety, and Immunogenicity Similarity of High‐ and Low‐Concentration Formulations of Adalimumab Biosimilar ABP 501, Adalimumab‐Atto

2026 · Vincent Chow, Muhan Zhou, et al. · Pharmacology Research & Perspectives

Late Breaking Abstract - A Phase 1 trial to evaluate the safety, PK and target engagement of MTX-463, a monoclonal antibody inhibitor of WISP1

2025 · Jeffrey Bornstein, Ahad Sabet, et al. · European Respiratory Journal

Works count: 7

Citation count: 168

H-index: 3

I10-index: 2